Fibroblast growth factors in cancer: therapeutic possibilities

Bibliography

• ORNITZ DM, ITOH N: Fibroblast growth factors. Genome Biol. (2001) 2(3):1–12.
   Web of Science ®Google Scholar
• •Brief FGF/FGFR review; includes a summary of FGF knockout experiments.
   Google Scholar
• POWERS CJ, MCLESKEY SW,WELLSTEIN A: Fibroblast growth factors, their receptors and signalling. En doer. Relat. Cancer (2000) 7(3):165–197.
   PubMed Web of Science ®Google Scholar
• ••Thorough FGF/FGFR review; includes adiscussion of the role of HSPG in FGF/ FGFR signalling.
   Google Scholar
• SZEBENYI G, FALLON JF: Fibroblast growth factors as multifunctional signalling factors. hat. Rev Cytol. (1999) 185:45–106.
   PubMedGoogle Scholar
• ••Complete FGF/FGFR review.
   Google Scholar
• KLINT P, CLAESSON-WELSH L: Signaltransduction by fibroblast growth factor receptors. Front Biosci. (1999) 4:D165–D177.
   Google Scholar
• KIM HS: The human FGF gene family: chromosome location and phylogenetic analysis. Cytogenet. Cell Genet. (2001) 93(1-2):131–132.
   PubMedGoogle Scholar
• TASSI E, AL-ATTAR A, AIGNER A et al.: Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. Biol. Chem. (2001) 276(43):40247–40253.
   Web of Science ®Google Scholar
• WU DQ, KAN MK, SATO GH, OKAMOTO T, SATO JD: Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. I. Biol. Chem. (1991) 266(25):16778–16785.
   Web of Science ®Google Scholar
• CZUBAYKO F, SMITH RV,CHUNG HC, WELLSTEIN A: Tumour growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J. Biol. Chem. (1994) 269(45):28243–28248.
   PubMed Web of Science ®Google Scholar
• AIGNER A, BUTSCHEID M,KUNKEL P et al.: An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumour cell and endothelial cell proliferation through FGF-2 release. Int. J. Cancer (2001) 92(4):510–517.
   Google Scholar
• FURTHAUER M, LIN W, ANG SL, THISSE B, THISSE C: Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat. Cell Biol. (2002) 4(2):170–174.
   PubMed Web of Science ®Google Scholar
• TSANG M, FRIESEL R, KUDOH T, DAWID IB: Identification of Sef, a novel modulator of FGF signalling. Nat. Cell Biol. (2002) 4(2):165–169.
   PubMed Web of Science ®Google Scholar
• ALOY P, RUSSELL RB: Interrogating protein interaction networks through structural biology. Proc. Nati Acad. Sci. USA (2002) 23:23.
   Google Scholar
• SCHOORLEMMER J, GOLDFARB M: Fibroblast growth factor homologous factors are intracellular signalling proteins. Can: Biol. (2001) 11(10):793–797.
   Google Scholar
• XIE MH, HOLCOMB I, DEUEL B et al: FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine (1999) 11(10):729–735.
   PubMed Web of Science ®Google Scholar
• TOMLINSON E, FU L, JOHN L et al: Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology (2002) 143(5):1741–1747.
   PubMed Web of Science ®Google Scholar
• NICHOLES K, GUILLET S,TOMLINSON E et al.: A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol (2002) 160(6):2295–2307.
   Google Scholar
• SHIMADA T, MIZUTANI S, MUTO T et al.: Cloning and characterization of FGF23 as a causative factor of tumour-induced osteomalacia. Proc. Nati Acad. Sci. USA (2001) 98(11):6500–6505.
   PubMed Web of Science ®Google Scholar
• •Shows that tumours associated with phosphate-wasting syndrome overexpress FGF-23 and expression of this protein induces phosphate-wasting syndrome in animals.
   Google Scholar
• WHITE KE, EVANS WE,O'RIORDAN JLH et al.: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat. Genet. (2000) 26(3):345–348.
   Google Scholar
• BOWE AE, FINNEGAN R, JAN DE BEUR SM et al.: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem. Biophys. Res. Commun. (2001) 284(4):977–981.
   Google Scholar
• UENO S, ITO J, NAGAYASU Y, FURUKAWA T, YOKOYAMA S: An acidic fibroblast growth factor-like factor secreted into the brain cell culture medium upregulates apoE synthesis, HDL secretion and cholesterol metabolism in rat astrocytes. Biochim. Biophys. Acta (2002) 1589(3):261–272.
   PubMed Web of Science ®Google Scholar
• NUMAKAWA T, YOKOMAKU D, KIYOSUE K et al: Basic fibroblast growth factor evokes a rapid glutamate release through activation of the MAPK pathway in cultured cortical neurons. Biol. Chem. (2002) 28:28.
   Google Scholar
• TAIRA M, YOSHIDA T,MIYAGAWA K et al.: cDNA sequence of human transforming gene hst and identification of the coding sequence required for transforming activity. Proc. Nati Acad. Sci. USA (1987) 84(9):2980–2984.
   Google Scholar
• JEFFERS M, SHIMKETS R,PRAYAGA S et al: Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res. (2001) 61(7):3131–3138.
   PubMed Web of Science ®Google Scholar
• ROPIQUET F, HUGUENIN S, VILLETTE JM et al: FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int. J. Cancer (1999) 82(2):237–243.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO-YOSHITOMI S, HABASHITA J, NOMURA C, KUROSHIMA K, KUROKAWA T: Autocrine transformation by fibroblast growth factor 9 (FGF-9) and its possible participation in human oncogenesis. Int. .1. Cancer (1997) 7 1 (3):442–450.
   Google Scholar
• DELLI BOVI P, CURATOLA AM, KERN FG et al.: An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell (1987) 50(5):729–737.
   PubMed Web of Science ®Google Scholar
• GOLDFARB M, DEED R,MACALLAN D et al: Cell transformation by Int-2: a member of the fibroblast growth factor family. Oncogene (1991) 6(1):65–71.
   PubMed Web of Science ®Google Scholar
• HAJITOU A, CALBERG-BACQ CM: Fibroblast growth factor 3 is tumorigenic for mouse mammary cells orthotopically implanted in nude mice. Int. J. Cancer (1995) 63(5):702–709.
   PubMed Web of Science ®Google Scholar
• JAYE M, LYALL RIVI, MUDD R, SCHLESSINGER J, SARVER N: Expression of acidic fibroblast growth factor cDNA confers growth advantage and tumourigenesis to Swiss 3T3 cells. EMBOI. (1988) 7(4):963–969.
   PubMed Web of Science ®Google Scholar
• MACARTHUR CA, LAWSHE A, SHANKAR DB, HEIKINHEIMO M, SHACKLEFORD GM: FGF-8 isoforms differ in NIH3T3 cell transforming potential. Cell Growth Differ. (1995) 6(7):817–825.
   PubMedGoogle Scholar
• DAPHNA-IKEN D, SHANKAR DB, LAWSHE A et al.: MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia. Oncogene (1998) 17(21):2711–2717.
   PubMed Web of Science ®Google Scholar
• CLARK JC, TICHELAAR JW,WERT SE et al.: FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo. Jim. j Physiol Lung Cell Mol Physiol (2001) 280(4)1705–L715.
   Google Scholar
• MORINI M, ASTIGIANO S,MORA M et al.: Hyperplasia and impaired involution in the mammary gland of transgenic mice expressing human FGF4. Oncogene (2000) 19(52):6007–6014.
   Google Scholar
• KITSBERG DI, LEDER P: Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene (1996) 13(12):2507–2515.
   PubMed Web of Science ®Google Scholar
• NGUYEN HQ, DANILENKO DM, BUCAY N et al: Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations. Oncogene (1996) 12(10):2109–2119.
   PubMed Web of Science ®Google Scholar
• TALARICO D, ITTMANN MM, BRONSON R, BASILICO C: A retrovirus carrying the k-FGF oncogene induces diffuse meningeal tumours and soft-tissue fibrosarcomas. Ma Cell. Biol. (1993) 13(4):1998–2010.
   Web of Science ®Google Scholar
• GROSS JL, HERBLIN WF,DUSAK BA et al.: Effects of modulation of basic fibroblast growth factor on tumour growth in vivo. I Nat! Cancer Inst. (1993) 85(2):121–131.
   Google Scholar
• LEITH JT, PAPA G, QUARANTO L, MICHELSON S: Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin. Br. Cancer (1992) 66(2):345–348.
   Google Scholar
• KRUCZYNSKI A, ASTRUC J,CHAZOTTES E, KISS R: Characterization of the hormone-sensitivity of three human nonsmall-cell lung cancers grafted onto nude mice. Oncology (1993) 50(4):285–292.
   PubMed Web of Science ®Google Scholar
• FIDLER IJ: Angiogenesis and cancer metastasis. Cancer J. Sri. Am. (2000) 6\(Suppl. 2):5134–5141.
   Google Scholar
• FOLKMAN J: Angiogenesis and angiogenesis inhibition: an overview. Experientia Supplementum (1997) 79:1–8.
   PubMedGoogle Scholar
• KLEIN S, ROGHANI M, RIFKIN DB: Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. Experientia Supplementum (1997) 79:159–192.
   PubMedGoogle Scholar
• DAMEN JE, GREENBERG AH, WRIGHT JA: Transformation and amplification of the k-FGF proto-oncogene in NIH-3T3 cells and induction of metastatic potential. Biochim. Biophys. Acta (1991) 1097(2):103–110.
   PubMedGoogle Scholar
• MIYAKE H, HARA I,YOSHIMURA K et al.: Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res. (1996) 56(10):2440–2445.
   Google Scholar
• LO J, HURTA RA: Overexpression of k-FGF or bFGF results in altered expression of matrix metalloproteinases: correlations with malignant progression and cellular invasion. Cell Biol. hat. (2002) 26(4):319–325.
   Google Scholar
• ZANG XP, PENTO JT: Keratinocyte growth factor-induced motility of breast cancer cells. Gin. Exp. Metastasis (2000) 18(7):573–580.
   PubMed Web of Science ®Google Scholar
• GRANERUS M, ENGSTROM W: Dual effects of four members of the fibroblast growth factor member family on multiplication and motility in human teratocarcinoma cells in vitro. Anticancer Res. (2000) 20(5B):3527–3531.
   Google Scholar
• GARDNER AM, JOHNSON GL: Fibroblast growth factor-2 suppression of tumour necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. J. Biol. Chem. (1996) 271(24):14560–14566.
   PubMed Web of Science ®Google Scholar
• SONG S, WIENTJES MG, GAN Y, AU JL: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Nat] Acad. Sri. USA (2000) 97(15):8658–8663.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that FGFs mediate tumour cell resistance to a variety of chemotherapeutic drugs.
   Google Scholar
• MIYAKE H, HARA I, GOHJI K et al.: Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett. (1998) 123(2):121–126.
   PubMed Web of Science ®Google Scholar
• MENZEL T, RAHMAN Z,CALLEJA E et al.: Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukaemia and is associated with resistance to fludarabine. Blood (1996) 87(3):1056–1063.
   Google Scholar
• JUNG M, KERN FG,JORGENSEN TJ et al.: Fibroblast growth factor-4 enhanced G2 arrest and cell survival following ionizing radiation. Cancer Res. (1994) 54(19):5194–5197.
   Google Scholar
• WHITE KE, JONSSON KB,CARN G et al: The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumours that cause phosphate wasting.Endocrinol Metab. (2001) 86(2):497–500.
   Google Scholar
• JACQUEMIER J, ADELAIDE J, PARC P et al: Expression of the FGFR1 gene in human breast-carcinoma cells. Int. Cancer (1994) 59(3):373–378.
   PubMed Web of Science ®Google Scholar
• CHESI M, NARDINI E,BRENTS LA et al.: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. (1997) 16(3):260–264.
   Google Scholar
• RICHELDA R, RONCHETTI D, BALDINI L et al.: A novel chromosomal translocation t(4; 14) (p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood (1997) 90(10):4062–4070.
   Google Scholar
• PLOWRIGHT EE, LIZ,BERGSAGEL PL et al.: Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood (2000) 95(3):992–998.
   Google Scholar
• PEGRAM M, SLAMON D: Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin. Onto] (2000) 27(5 Sunni. 9):13–19.
   Google Scholar
• CHESI M, BRENTS LA, ELY SA et al: Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumour progression in multiple myeloma. Blood (2001) 97(3):729–736.
   PubMed Web of Science ®Google Scholar
• FURITSU T, TSUJIMURA T,TONO T et al.: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukaemia cell line causing ligand-independent activation of c-kit product. Gin. Invest. (1993) 92(4):1736–1744.
   Google Scholar
• SANTORO M, CARLOMAGNO F, ROMANO A et al: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (1995) 267(5196):381–383.
   PubMed Web of Science ®Google Scholar
• JEFFERS M, SCHMIDT L,NAKAIGAWA N et al.: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA (1997) 94(21):11445–11450.
   Google Scholar
• PIAO X, PAULSON R,VAN DER GEER P, PAWSON T, BERNSTEIN A: Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Nati Acad. Sci. USA (1996) 93(25):14665–14669.
   PubMed Web of Science ®Google Scholar
• HART KC, ROBERTSON SC, KANEMITSU MY et al.: Transformation and Stat activation by derivatives of FGFR1, FGFR3 and FGFR4. Oncogene (2000) 19(29):3309–3320.
   PubMed Web of Science ®Google Scholar
• CAPPELLEN D, DE OLIVEIRA C, RICOL D et al.: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. (1999) 23(1):18–20.
   PubMed Web of Science ®Google Scholar
• •Identification of activating mutations in FGFR3 in 25% (3/12) cervical carcinomas and somatic activating mutations in 35% (9/26) bladder carcinomas examined.
   Google Scholar
• LIZ, ZHU YX, PLOWRIGHT EE et al:The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood (2001) 97(8):2413–2419.
   PubMed Web of Science ®Google Scholar
• •Demonstration of weak or strong oncogenicity of wild type or mutationally activated FGFR3, respectively, in an in vivo model.
   Google Scholar
• EZZAT S, ZHENG L, ZHU XF, WU GE, ASA SL: Targeted expression of a human pituitary tumour-derived isoform of FGF receptor-4 recapitulates pituitary tumourigenesis. Clin. Invest. (2002) 109(1):69–78.
   Google Scholar
• •Identification of a novel, constitutively activated, N-terminally-truncated FGFR4 in a human pituitary tumour and demonstration that this oncogene causes pituitary tumours in transgenic mice.
   Google Scholar
• SMEDLEY D, HAMOUDI R,CLARK J et al: The t(8;13) (p 1 1;q 11– 12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP Hum. Mol. Genet. (1998) 7(4):637–642.
   Google Scholar
• DEMIROGLU A, STEER EJ,HEATH C et al.: The t(8;22) in chronic myeloid leukaemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood (2001) 98(13):3778–3783.
   Google Scholar
• •Demonstrates transforming activity of a tumour-associated FGFR1 fusion protein and inhibition of transformation with a tyrosine-kinase inhibitor and inibitors of signalling molecules.
   Google Scholar
• POPOVICI C, ADELAIDE J,OLLENDORFF V et al: Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc. Nati Acad. Sci. USA (1998) 95(10):5712–5717.
   PubMed Web of Science ®Google Scholar
• POPOVICI C, ZHANG B,GREGOIRE MJ et al: The t(6,8) (q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood(1999) 93(4):1381–1389.
   PubMed Web of Science ®Google Scholar
• REITER A, SOHAL J,KULKARNI S et al.: Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13) (p11;q12) myeloproliferative syndrome. Blood (1998) 92(5):1735–1742.
   Google Scholar
• XIAO S, NALABOLU SR,ASTER JC et al.: FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet. (1998) 18(1):84–87.
   Google Scholar
• GUASCH G, MACK GJ,POPOVICI C et al.: FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t (8;9) (p12; q33). Blood (2000) 95(5):1788–1796.
   Google Scholar
• MANSOUR SL: Targeted disruption of Int-2 (FGF-3) causes developmental defects in the tail and inner ear. Mol. Reprod. Dev. (1994) 39(1):62–67; discussion 67–68.
   Google Scholar
• TERADA M, YOSHIDA T, SAKAMOTO H et al: Biological significance of the hst-1 gene. Princess Takamatsu Symp. (1989) 20:71–80.
   PubMedGoogle Scholar
• LISCIA DS, MERLO GR,GARRETT C et al.: Expression of Int-2 mRNA in human tumours amplified at the Int-2 locus. Oncogene (1989) 4(10):1219–1224.
   Google Scholar
• LESE CM, ROSSIE KM, APPEL BN et al:Visualization of INT2 and HST1amplification in oral squamous cell carcinomas. Genes Chromosomes Cancer(1995) 12(4):288–295.
   PubMed Web of Science ®Google Scholar
• TSUDA T, TAHARA E,KAJIYAMA G et al.: High incidence of coamplification of hst-1 and Int-2 genes in human esophageal carcinomas. Cancer Res. (1989) 49(20):5505–5508.
   Google Scholar
• KIURU-KUHLEFELT S,SARLOMO-RIKALA M, LARRAMENDY ML et al.: FGF4 and INT2 oncogenes are amplified and expressed in Kaposi's sarcoma. Mod. Pathol. (2000) 13(4):433–437.
   Google Scholar
• HUANG YQ, LI JJ,MOSCATELLI D et al.: Expression of Int-2 oncogene in Kaposi's sarcoma lesions. J. Clin. Invest. (1993) 91(3):1191–1197.
   Google Scholar
• NGUYEN M, WATANABE H,BUDS ON AE et al.: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. Nat! Cancer Inst. (1994) 86(5):356–361.
   Google Scholar
• RASMUSON T, GRANKVIST K, JACOBSEN J, LJUNGBERG B: Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Ear: J. Cancer (2001) 37(17):2199–2203.
   PubMed Web of Science ®Google Scholar
• LIN RY, ARGENTA PA, SULLIVAN KM, ADZICK NS: Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumour patients. Clin. Cancer Res. (1995) 1(3):327–331.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO K, ICHIMORI Y, YAMAGUCHI H et al.: Basic fibroblast growth factor as a candidate tumour marker for renal cell carcinoma. fpn J. Cancer Res. (1995) 86(2):182–186.
   PubMedGoogle Scholar
• NGUYEN M, WATANABE H,BUDS ON AE, RICHIE JP, FOLKMAN J: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Nat! Cancer Inst. (1993) 85(3):241–242.
   PubMedGoogle Scholar
• LEUNIG A, TAUBER S, SPAETT R, GREVERS G, LEUNIG M: Basic fibroblast growth factor in serum and urine of patients with head and neck cancer. Oncol. Rep. (1998) 5(4):955–958.
   PubMed Web of Science ®Google Scholar
• LANDRISCINA M, CASSANO A, RATTO C et al.: Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br. J. Cancer (1998) 78(6):765–770.
   PubMed Web of Science ®Google Scholar
• UGUREL S, RAPPL G, TILGEN W, REINHOLD U: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumour progression and survival. Clin. Oncol (2001) 19(2):577–583.
   Web of Science ®Google Scholar
• UENO K, INOUE Y, KAWAGUCHI T, HOSOE S, KAWAHARA M: Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer (2001) 31(2-3):213–219.
   PubMed Web of Science ®Google Scholar
• KURIMOTO M, ENDO S, HIRASHIMA Y, NISHIJIMA M, TAKAKU A: Elevated plasma basic fibroblast growth factor in brain tumour patients. Neurol Med. Chir: (Tokyo) (1996) 36(12):865–868; discussion 869.
   Google Scholar
• GRAEVEN U, ANDRE N, ACHILLES E, ZORNIG C, SCHMIEGEL W: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. " Cancer Res. Clin. Oncol (1999) 125(10):577–581.
   Google Scholar
• SALVEN P, TEERENHOVI L,JOENSUU H: A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non Hodgkin's lymphoma. Blood (1999) 94(10):3334–3339.
   PubMed Web of Science ®Google Scholar
• POON RT, NG 10, LAU C et al: Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. Surg. (2001) 182(3):298–304.
   Google Scholar
• LI Y, BASILICO C, MANSUKHANI A: Cell transformation by fibroblast growth factors can be suppressed by truncated fibroblast growth factor receptors. Ma Cell. Biol. (1994) 14(11):7660–7669.
   Web of Science ®Google Scholar
• HORI A, SASADA R,MATSUTANI E et al.: Suppression of solid tumour growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. (1991) 51(22):6180–6184.
   Google Scholar
• HOFFMAN RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs (1999) 17(4):343–359.
   PubMed Web of Science ®Google Scholar
• KUO TH, KUBOTA T,WATANABE M et al.: Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models toobtain relevant drug evaluation data.Anticancer Res. (1993) 13(3):627–630.
   Google Scholar
• WILMANNS C, FAN D, O'BRIAN CA, BUCANA CD, FIDLER IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5- fluorouracil. Int. Cancer (1992) 52(1):98–104.
   PubMed Web of Science ®Google Scholar
• CHANDLER LA, SOSNOWSKI BA, GREENLEES L et al.: Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumour cell lines. hat. J. Cancer (1999) 81(3):451–458.
   PubMed Web of Science ®Google Scholar
• •Expression analysis of FGFRs in 60 human cancer cell lines.
   Google Scholar
• BECKER D, LEE PL, RODECK U, HERLYN M: Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene (1992) 7(11):2303–2313.
   PubMed Web of Science ®Google Scholar
• YAMADA SM, YAMAGUCHI F,BROWN R, BERGER MS,MORRISON RS: Suppression of glioblastoma cell growth following antisense oligonucleotide-mediated inhibition of fibroblast growth factor receptor expression. QM (1999) 28(1):66–76.
   Google Scholar
• WANG Y, BECKER D: Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoural angiogenesis and tumour growth. Nat. Med. (1997) 3(8):887–893.
   PubMed Web of Science ®Google Scholar
• WAGNER M, LOPEZ ME, CAHN M, KORC M: Suppression of fibroblast growth factor receptor signalling inhibits pancreatic cancer growth M vitro and in vivo. Gastroenterology (1998) 114(4):798–807.
   PubMed Web of Science ®Google Scholar
• OZEN M, GIRI D, ROPIQUET F, MANSUKHANI A, ITTMANN M: Role of fibroblast growth factor receptor signalling in prostate cancer cell survival. Nat! Cancer Inst. (2001) 93(23):1783–1790.
   PubMed Web of Science ®Google Scholar
• SAIKI M, MIMA T,TAKAHASHI JC et al.: Adenovirus-mediated gene transfer of a truncated form of fibroblast growth factor receptor inhibits growth of glioma cells both M vitro and in vivo. J. Neurooncol (1999) 44(3):195–203.
   Google Scholar
• DAVOL PA, BIZUNEH A,FRACKELTON AR JR: Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimaeras M vitro andM vivo. Anti-Cancer Res. (1999)19(3A):1705–1713.
   Google Scholar
• •Analysis of six different toxin-conjugates targeting FGFR; demonstration that combination therapy with a PI3K inhibitor enhances tumour-killing efficacy in vitro and in vivo.
   Google Scholar
• DAVOL P, BEITZ JG, MOHLER M et al: Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Cancer (1995) 76(1)79–85.
   Google Scholar
• SHAWVER LK, SLAMON D,ULLRICH A: Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell (2002) 1:117–123.
   PubMed Web of Science ®Google Scholar
• •Discussion of clinical findings using antibody or small molecule inhibitors of tyrosine kinases for cancer therapy.
   Google Scholar
• HALUSKA P, ADJEI AA: Receptor tyrosine kinase inhibitors. Curt: Opin. Investig. Drugs(2001) 2(2):280–286.
   PubMedGoogle Scholar
• •Discussion of the biology and clinical development of small molecule inhibitors of tyrosine kinases for cancer therapy.
   Google Scholar
• ZHAO Y, LOUD, BURKETT J, KOHLER H: Chemical engineering of cell penetrating antibodies. I Immunol Methods (2001) 254(1-2):137–145.
   PubMed Web of Science ®Google Scholar
• VISINTIN M, SETTANNI G, MARITAN A et al.: The intracellular antibody capture technology (TACT): towards a consensus sequence for intracellular antibodies.' Ma Biol. (2002) 317(1):73–83.
   PubMed Web of Science ®Google Scholar
• CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev Cancer (2001) 1(2):118–129.
   PubMed Web of Science ®Google Scholar
• ••Complete review of antibodies as cancertherapeutics.
   Google Scholar
• WHITE CA, WEAVER RL,GRILLO-LOPEZ AJ: Antibody-targeted immunotherapy for treatment of malignancy. Ann. Rev Med. (2001) 52:125–145.
   PubMed Web of Science ®Google Scholar
• •Thorough review of antibodies as cancer therapeutics.
   Google Scholar
• XU G, MCLEOD HL: Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. (2001) 7(11):3314–3324.
   PubMed Web of Science ®Google Scholar
• •Thorough review of gene (GDEPT), virus (VDEPT) and ADEPT as cancer therapeutics.
   Google Scholar
• CHART RV: Targeted delivery of chemotherapeutics: tumour-activated prodrug therapy. Adv. Drug Deify. Rev (1998) 31(1-2):89–104.
   PubMed Web of Science ®Google Scholar
• •Thorough review of tumour-activated prodrug cancer therapy.
   Google Scholar
• KREITMAN RJ: Toxin-labelled monoclonal antibodies. Carr: Pharm. Biotechnol (2001) 2(4):313–325.
   PubMedGoogle Scholar
• •Thorough review of use of conjugated antibodies as cancer therapeutics.
   Google Scholar
• REITER Y: Recombinant immunotoxins in targeted cancer cell therapy. Adv. Cancer Res. (2001) 81:93–124.
   PubMed Web of Science ®Google Scholar
• •Thorough review of the use of conjugated antibodies as cancer therapeutics; includes information on use of growth factor-toxin conjugates in cancer therapy.
   Google Scholar
• CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumour targets. Nat. Med. (2000) 6(4):443–446.
   PubMed Web of Science ®Google Scholar
• DYER MJ, HALE G, HAYHOE FG, WALDMANN H: Effects of CAMPATH-1 antibodies M vivoin patients with lymphoid malignancies: influence of antibody isotype. Blood(1989) 73(6):1431–1439.
   PubMed Web of Science ®Google Scholar
• IWAHASHI T, OKOCHI E,ARIYOSHI K et al.: Specific targeting and killing activities of antiP-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res. (1993) 53(22):5475–5482.
   Google Scholar
• IDUSOGIE EE, WONG PY,PRESTA LG et al.: Engineered antibodies with increased activity to recruit complement. J. Immunol (2001) 166(4):2571–2575.
   Google Scholar
• SHIELDS RL, NAMENUK AK,HONG K et al.: High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. (2001) 276(9):6591–6604.
   Google Scholar
• UMANA P, JEAN-MAIRET J,MOUDRY R, AMSTUTZ H, BAILEY JE: Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol (1999) 17(2):176–180.
   PubMed Web of Science ®Google Scholar
• HUGHES SE: Differential expression of the fibroblast growth factor receptor (FM) multigene family in normal human adult tissues. I Histochem. Cytochem. (1997) 45(7):1005–1019.
   PubMed Web of Science ®Google Scholar
• •Thorough irnmunohistochemical analysis of FGFR expression in normal human adult tissues.
   Google Scholar
• INOUE K, WOOD CG,SLATON JW et al: Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Omni Rep. (2001) 8(5):955–964.
   Google Scholar
• MORRISON RS: Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. Biol. Chem. (1991) 266(2):728–734.
   Web of Science ®Google Scholar
• MORRISON RS, GIORDANO S, YAMAGUCHI F et al.: Basic fibroblast growth factor expression is required for clonogenic growth of human glioma cells.' NeuroscL Res. (1993) 34(5):502–509.
   PubMed Web of Science ®Google Scholar
• STAN AC, NEMATI MN, PIETSCH T, WALTER GF, DIETZ H: In vivoinhibition of angiogenesis and growth of the human U-87 malignant glial tumour by treatment with an antibody against basic fibroblast growth factor. Neurosurg. (1995) 82(6):1044–1052.
   Web of Science ®Google Scholar
• MURAI N, UEBA T,TAKAHASHI JA et al.: Apoptosis of human glioma cells M vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. Neurosurg. (1996) 85(6):1072–1077.
   Google Scholar
• TAKAHASHI JA, FUKUMOTO M, KOZAI Y et al.: Inhibition of cell growth and tumourigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett. (1991) 288(1-2):65–71.
   PubMed Web of Science ®Google Scholar
• FINCH PW, YEE LK, CHU MY et al.: Inhibition of growth factor mitogenicity and growth of tumour cell xenografts by a sulfonated distamycin A derivative. Pharmacology (1997) 55(6):269–278.
   PubMed Web of Science ®Google Scholar
• WELLSTEIN A, ZUGMAIER G, CALIFANO JA 3RD et al.: Tumour growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate.J. Nat! Cancer Inst. (1991) 83(10):716–720.
   Google Scholar
• PLUM SM, HOLADAYJW, RUIZ A et al: Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumour development. Vaccine (2000) 19(9-10):1294–1303.
   PubMed Web of Science ®Google Scholar
• BAIRD A, SCHUBERT D, LING N, GUILLEMIN R: Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc. Nati Acad. Sci. USA (1988) 85(7):2324–2328.
   PubMed Web of Science ®Google Scholar
• BOTTARO DP, FORTNEY E, RUBIN JS, AARONSON SA: A keratinocyte growth factor receptor-derived peptide antagonist identifies part of the ligand binding site. J. Biol. Chem. (1993) 268(13):9180–9183.
   PubMed Web of Science ®Google Scholar
• FLOEGE J, OSTENDORF T,JANSSEN U et al.: Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. Pathol (1999) 154(1):169–179.
   Google Scholar
• CAO B, SU Y, OSKARSSON M et al: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumour activity in animal models. Proc. Nati Acad. Sci. USA (2001) 98(13):7443–7448.
   PubMed Web of Science ®Google Scholar
• CZUBAYKO F,LIAUDET-COOPMAN ED,AIGNER A et al: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat. Med. (1997) 3(10):1137–1140.
   PubMed Web of Science ®Google Scholar
• MATSUDA K, MARUYAMA H, GUO F et al.: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. (2001) 61(14):5562–5569.
   PubMed Web of Science ®Google Scholar
• HUNTER T: Oncoprotein networks. Cell (1997) 88(3):333–346.
   PubMed Web of Science ®Google Scholar
• ADJEI AA: Signal transduction pathway targets for anticancer drug discovery. Curr. Pharm. Des (2000) 6(4):361–378.
   PubMed Web of Science ®Google Scholar
• SAHNI M, AMBROSETTI DC, MANSUKHANI A et al.: FGF signalling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. (1999) 13(11):1361–1366.
   PubMed Web of Science ®Google Scholar
• AIKAWA T, SEGRE GV, LEE K: Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J. Biol. Chem. (2001) 276(31):29347–29352.
   PubMed Web of Science ®Google Scholar
• WESTWOOD G, DIBLING BC, CUTHBERT-HEAVENS D,BURCHILL SA: Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway. Oncogene (2002) 21(5):809–824.
   PubMed Web of Science ®Google Scholar
• SCHWEIGERER L, NEUFELD G, GOSPODAROWICZ D: Basic fibroblast growth factor as a growth inhibitor forcultured human tumour cells. J. Clin. Invest.(1987) 80(5):1516–1520.
   PubMed Web of Science ®Google Scholar
• •Early report of FGF-mediated inhibition of tumour (Ewing's sarcoma) growth; prelude of things to come.
   Google Scholar
• SMITS VA, VAN PEER MA,ESSERS MA et al.: Negative growth regulation of SK-N-MC cells by bEGF defines a growth factor-sensitive point in G2. J. Bid/. Chem. (2000) 275(25):19375–19381.
   Google Scholar
• STURLA LM, WESTWOOD G, SELBY PJ, LEWIS IJ, BURCHILL SA: Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma. Cancer Res. (2000) 60(21):6160–6170.
   PubMed Web of Science ®Google Scholar
• DUPLAN SM, THEORET Y,KENIGSBERG RL: Antitumour activity of fibroblast growth factors (FGEs) for medulloblastoma may correlate with FGF receptor expression and tumour variant. Clin. Cancer Res. (2002) 8(1):246–257.
   PubMedGoogle Scholar
• DERRINGTON EA, DUFAY N, RUDKIN BB, BELIN MF: Human primitive neuroectodermal tumour cells behave as multipotent neural precursors in response to FGF2. Oncogene (1998) 17(13):1663–1672.
   PubMed Web of Science ®Google Scholar
• NIBU K, LI G, KAGA K,ROTHSTEIN JL: bEGF induces differentiation and death of olfactory neuroblastoma cells. Biochem. Biophys. Res. Commun. (2000) 279(1):172–180.
   PubMed Web of Science ®Google Scholar
• RAGUENEZ G, DESIRE L,LANTRUA V, COURTOIS Y: BCL-2 is upregulated in human SH-SY5Y neuroblastoma cells differentiated by overexpression of fibroblast growth factor 1. Biochem. Biophys. Res. Commun. (1999) 258(3):745–751.
   PubMed Web of Science ®Google Scholar
• ROCKOW S, TANG J, XIONG W, LI W: Nck inhibits NGF and basic FGF induced PC12 cell differentiation via mitogen-activated protein kinase-independent pathway. Oncogene (1996) 12(11):2351–2359.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, WANG H,TORATANI S et al.: Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc. Natl Acad. Sci. USA (2001) 98(20):11336–11340.
   Google Scholar
• MATSUBARA A, KAN M, FENG S, MCKEEHAN WL: Inhibition of growth of malignant rat prostate tumour cells by restoration of fibroblast growth factorreceptor 2. Cancer Res. (1998) 58 (7):1509–1514.
   PubMed Web of Science ®Google Scholar
• FENG S, WANG F, MATSUBARA A, KAN M, MCKEEHAN WL: Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res. (1997) 57(23):5369–5378.
   PubMed Web of Science ®Google Scholar
• MCLESKEY SW, DING TY,LIPPMAN ME, KERN FG: MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res. (1994) 54(2):523–530.
   PubMed Web of Science ®Google Scholar
• WANG H, RUBIN M, FENIG E et al: Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res. (1997) 57(9):1750–1757.
   PubMed Web of Science ®Google Scholar
• EVES EM, SKOCZYLAS C, YOSHIDA K, ALNEMRI ES, ROSNER MR: FGF induces a switch in death receptor pathways in neuronal cells. Neurosci. (2001) 21(14):4996–5006.
   Web of Science ®Google Scholar
• REILAND J, RAPRAEGER AC: Heparan sulfate proteoglycan and FGF receptor target basic FGF to different intracellular destinations. J. Cell Sci. (1993)105(Pt 4):1085–1093.
   PubMedGoogle Scholar
• COLL-FRESNO PM, BATOZ M, TARQUIN S, BIRNBAUM D, COULIER F: Cytotoxic activity of a diptheria toidm/FGF6 mitotoxin on human tumour cell lines. Oncogene (1997) 14(2):243–247.
   PubMed Web of Science ®Google Scholar
• GAWLAK SL, PASTAN I, SIEGALL CB: Basic fibroblast growth factor-Pseudomonas exotwdn chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoidn. Bioconjug. Chem. (1993) 4(6):483–489.
   PubMed Web of Science ®Google Scholar
• SIEGALL CB, GAWLAK SL, CHACE DF, MERWIN JR, PASTAN I: In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins. Bioconjug. Chem. (1994) 5(1):77–83.
   PubMed Web of Science ®Google Scholar
• DAVOL PA, FRACKELTON AR JR: Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumour resistance. Prostate (1999) 40(3):178–191.
   PubMed Web of Science ®Google Scholar
• SCHMIDT A, MOCKEL B, ECK J et al.: Cytotoxic activity of recombinant bEGF-rViscumin fusion proteins. Biochem.Biophys. Res. Commun. (2000) 277(2):499–506.
   PubMed Web of Science ®Google Scholar
• FUTAMI J, SENO M, UEDA M, TADA H, YAMADA H: Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Protein Engl. (1999) 12 (11):1013–1019.
   PubMedGoogle Scholar
• DAVOL PA, GARZA S,FRACKELTON AR JR: Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model. Cancer (1999) 86(9):1733–1741.
   PubMed Web of Science ®Google Scholar
• GU DL, GONZALEZ AM,PRINTZ MA et al.: Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumour activity in mice. Cancer Res. (1999) 59(11)2608–2614.
   Google Scholar
• KLEEFF J, FUKAHT K, LOPEZ ME et al: Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther. (2002) 9(6):522–532.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL C, KARTHAUS M, GANSER A: New strategies in the treatment and prophylaxis of chemo- and radiotherapy-induced oral mucositis. Antibia Chemother. (2000) 50:115–132.
   PubMedGoogle Scholar
• DANILENKO DM: Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol. Pathol. (1999) 27(1):64–71.
   PubMed Web of Science ®Google Scholar
• BOOTH D, POTTEN CS: Protection against mucosal injury by growth factors and cytokines. Nat! Cancer Inst. Monogr. (2001) 29:16–20.
   Google Scholar
• KONISHI H, OCHIYA T,SAKAMOTO H et al: Effective prevention of thrombocytopenia in mice using adenovirus-mediated transfer of HST-1 (FGF-4) gene. I Clin. Invest. (1995) 96(2):1125–1130.
   PubMed Web of Science ®Google Scholar
• OKUNIEFF P, ABRAHAM EH,MOINI M et al.: Basic fibroblast growth factor radioprotects bone marrow and not RIF1 tumour. Acta Oncol (1995) 34(3):435–438.
   Google Scholar
• TAKAHAMA Y, OCHIYA T,TANOOKA H et al.: Adenovirus-mediated transfer of HST-1/FGF-4 gene protects mice from lethal irradiation. Oncogene (1999) 18(43):5943–5947.
   Google Scholar
• MIND, TAYLOR PA,PANOSKALTSTS-MORTART A et al.:Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T cell reconstitution after bone marrow transplantation. Blood (2002) 99 (12) :4 5 92–4600.
   Google Scholar
• YAMAMOTO H, OCHIYA T,TAMAMUSHI S et al: HST-1/FGF-4 gene activation induces spermatogenesis and prevents adriamycin-induced testicular toxicity. Oncogene (2002) 21(6)899–908.
   Google Scholar
• DAVIES MM, BURKE D,CARNOCHAN P et al: Basic fibroblast growth factor infusion increases tumour vascularity, blood flow and chemotherapy uptake. Acta Oncol (2002) 41(1):84–90.
   PubMed Web of Science ®Google Scholar
• COLEMAN AB, MOMAND J, KANE SE: Basic fibroblast growth factor sensitizes NIH 3T3 cells to apoptosis induced by cisplatin. Mol. Phannacol (2000) 57(2)324–333.
   Google Scholar
• FENIG E, LIVNAT T,SHARKON-POLAK S et al.: Basic fibroblast growth factor potentiates cisplatinum-induced cytotoxicity in MCF-7 human breast cancer cells. J. Cancer Res. Cilia. Oncol (1999) 125(10):556–562.
   Google Scholar
• LEITH JT: Enhancement of thermal sensitivity of xenografted human DLD-2 tumours by administration of basic fibroblast growth factor. Radial Res. (1994) 138(1):139–142.
   PubMed Web of Science ®Google Scholar
• DING I, HUANG K, SNYDER ML et al.: Tumour growth and tumour radiosensitivity in mice given myeloprotective doses of fibroblast growth factors. Nat! Cancer Inst. (1996) 88(19):1399–1404.
   PubMedGoogle Scholar